Rheumatology

Spondyloarthritis

Questions discussed in this category

How long would you recommend that a patient continues guselkumab prior to deciding that the therapy is not effective?

In contrast to TNF inhibitors for psoriatic arthritis, which seem to peak and maintain response percentages, the DISCOVER-2 Trial (McInnes et al., PMI...

4 Answers available

How do you interpret treatment response in the DISCOVER-2 Trial when patients were allowed to remain on up to 10mg of prednisone equivalent for disease control while on guselkumab?

In clinical practice continued steroid dependence is often seen as a reason to switch therapy and providers can be especially hesitant to use systemic...

3 Answers available

Where in the sequence of biologics would you consider guselkumab for patients with active psoriatic arthritis despite standard DMARD therapy?

Based on the results of the DISCOVER-2 Trial (McInnes et al., PMID 34719872), should guselkumab be used prior to anti-TNF therapy in these patients?

3 Answers available

How do you manage inflammatory back pain when X-rays and MRI show no evidence of sacroiliitis?

Is an MRI necessary to diagnose non-radiographic axial spondyloarthritis?

1 Answer available

What has been your experience using apremilast to treat mild to moderate psoriatic arthritis not controlled with NSAIDs?

1 Answer available

How do you treat celiac disease associated inflammatory arthritis refractory to gluten free diet?

1 Answer available

What disease activity measures do you find helpful in clinical practice for psoriatic arthritis/peripheral spondyloarthritis?

1 Answer available

What studies do you find helpful to determine if an axial spondyloarthritis patient presenting late in the disease course with significant irreversible joint damage may benefit from immunosuppression?

1 Answer available

What is your approach to a patient with incidental radiographic findings of sacroiliitis without clinical inflammatory back pain?

2 Answers available

Are there any specific circumstances when you would consider the use of immunosuppression for DISH?

There is some emerging evidence that there is an inflammatory component.

1 Answer available

How do you approach screening for inflammatory bowel disease prior to starting IL-17 inhibitors?

1 Answer available

What do you use to treat uveitis refractory to conventional synthetic DMARDs and TNF inhibitors?

Are IL-17 or IL-23 inhibitors helpful?

5 Answers available

Are there any therapeutic options for cauda equina syndrome secondary to dural ectasia in end-stage ankylosing spondylitis?

1 Answer available

Do you image the spine in addition to the sacroiliac joints when you suspect axial spondyloarthritis?

Can axSpA affect the spine without affecting the sacroiliac joints?

1 Answer available

Do you recommend the use of contrast to identify sacroiliitis on MRI?

2 Answers available

What treatment options are available for patients with spondyloarthritis who develop biologic-induced psoriasis?

1 Answer available

Is there evidence that either ASDAS or BASDAI is superior for measuring clinical outcomes in axial spondyloarthritis?

1 Answer available

Would you use an IL-17 inhibitor for a psoriatic arthritis patient with inactive inflammatory bowel disease?

1 Answer available

What are specific treatment considerations for dactylitis- or enthesitis-predominant AxSpa/PsA?

1 Answer available

What are the benefits of sending HLA B27 genotype over HLA B27 antigen when evaluating for spondyloarthritis?

2 Answers available

Would you use an anti-IL 17 over an anti-TNFa as your first line biologic in psoriatic arthritis?

Have the SPIRIT H2H and EXCEED data changed your practice?

1 Answer available

What is the preferred DMARD in active spondyloarthropathy with psoriasis and sacroiliitis features in the setting of treated hepatitis C with negative viral load?

In patients refractory to NSAIDs and sulfasalazine

1 Answer available

What are some strategies for radiographically differentiating between erosions secondary to erosive osteoarthritis versus psoriatic arthritis involving the DIP joints?

1 Answer available

How do you differentiate between axial psoriatic arthritis and axial spondylitis with psoriasis, and is it important to distinguish between these two conditions from a prognostic and treatment perspective?

1 Answer available

Is it okay to use COX-2 selective NSAIDs in patients with IBD-associated arthritis when the IBD is in remission?

1 Answer available

What do you try in patients with IBD-related spondyloarthritis with predominantly axial symptoms who are refractory to TNF inhibitors?

1 Answer available

Papers discussed in this category

Annals of the rheumatic diseases, 2017-08

Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study.

Lancet (London, England), 2018-12-01

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.

Arthritis Rheumatol, 2019 Oct

2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.

Lancet, 2019 Nov 12

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial.

Cochrane Database Syst Rev, 2014 Oct 23

Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.

Arthritis Rheumatol, 2019 Jan

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

Ann. Rheum. Dis., 2019 Sep 28

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.

Lancet,

Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.

Arthritis & rheumatology (Hoboken, N.J.), 2016-05

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis.

Rheumatology (Oxford),

Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis?

Rheumatology (Oxford),

Axial disease in psoriatic arthritis.

Clin. Exp. Rheumatol., 2016 Dec 13

Clinical and genetic associations of radiographic sacroiliitis and its different patterns in psoriatic arthritis.

Lancet, 2015 Oct 01

Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial.

J Rheumatol Suppl,

GRAPPA 2018 Project Report.

Nat Rev Rheumatol,

Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison.

Rheumatology (Oxford),

Treatment guidelines in psoriatic arthritis.

Ann Rheum Dis, 2015 Dec 07

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.

J Med Imaging Radiat Oncol,

Gull-wing deformity: Osteoarthritis.

J Ultrason, 2016 Mar 29

Diagnostic imaging of psoriatic arthritis. Part I: etiopathogenesis, classifications and radiographic features.

Ophthalmology, 2015-05

Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy.

Retina,

LONG-TERM OUTCOMES OF RITUXIMAB THERAPY IN PATIENTS WITH NONINFECTIOUS POSTERIOR UVEITIS REFRACTORY TO CONVENTIONAL IMMUNOSUPPRESSIVE THERAPY.

Ophthalmic Res, 2018 Apr 10

Cyclophosphamide or Rituximab Treatment of Scleritis and Uveitis for Patients with Granulomatosis with Polyangiitis.

Dev Ophthalmol, 2012 Apr 17

Rituximab for noninfectious uveitis.

Arthritis Rheumatol, 2019 Aug 12

Long-Term Outcome of Ustekinumab Therapy for Behçet's Disease.

American journal of ophthalmology, 2017-11

Primary (Month-6) Outcomes of the STOP-Uveitis Study: Evaluating the Safety, Tolerability, and Efficacy of Tocilizumab in Patients With Noninfectious Uveitis.

Journal of spinal disorders, 2001-10

Cauda equina syndrome in ankylosing spondylitis (the CES-AS syndrome): meta-analysis of outcomes after medical and surgical treatments.

Arthritis Rheum,

Dramatic efficacy of infliximab in cauda equina syndrome complicating ankylosing spondylitis.

Annals of the rheumatic diseases, 2017-04

International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials.

Arthritis Care Res (Hoboken), 2018 Aug

Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis: Results From a Tight-Control Clinical Trial and an Observational Cohort.

Arthritis Care Res (Hoboken),

Measuring Outcomes in Psoriatic Arthritis.

Curr Rheumatol Rep,

Polymorphism of HLA-B27: 105 subtypes currently known.

Ann Rheum Dis, 2011 Jul 28

HLA-B27 positive patients differ from HLA-B27 negative patients in clinical presentation and imaging: results from the DESIR cohort of patients with recent onset axial spondyloarthritis.

Ann Rheum Dis,

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update.

J Rheumatol,

A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index.

Ann Rheum Dis, 2008 Jul 14

Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis.

Ann Rheum Dis, 2010 Nov 10

Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores.

Journal of psoriasis and psoriatic arthritis, 2019-04

TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management.

Front Pharmacol, 2019 Mar 26

Paradoxical Skin Reactions to Biologics in Patients With Rheumatologic Disorders.

Rheumatology (Oxford), 2013 Feb 16

Magnetic resonance imaging of the sacroiliac joints in the early detection of spondyloarthritis: no added value of gadolinium compared with short tau inversion recovery sequence.

Ann Rheum Dis, 2005 Jan 13

Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging: a comparison between contrast enhanced T1 and short tau inversion recovery (STIR) sequences.

Ann Rheum Dis, 2016 Jan 14

Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group.

Ann Rheum Dis, 2014 Jan 22

Does spinal MRI add incremental diagnostic value to MRI of the sacroiliac joints alone in patients with non-radiographic axial spondyloarthritis?

Ann Rheum Dis, 2012 May 14

Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study group.

Ann Rheum Dis, 2015 Aug 18

Patients with chronic back pain of short duration from the SPACE cohort: which MRI structural lesions in the sacroiliac joints and inflammatory and structural lesions in the spine are most specific for axial spondyloarthritis?

Arthritis Rheumatol, 2020 May

Effect of Therapy on Radiographic Progression in Axial Spondyloarthritis: A Systematic Review and Meta-Analysis.

Annals of the rheumatic diseases, 2009-06

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection.

Arthritis Care Res (Hoboken), 2019 Oct

2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.

Gut, 1999-04

Linkage of Crohn's disease to the major histocompatibility complex region is detected by multiple non-parametric analyses.

Gut, 2012-12

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

Annals of the rheumatic diseases, 2019-04

Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.

Ann Rheum Dis, 2014 Mar 21

The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study.

Current rheumatology reports, 2009-10

Diffuse idiopathic skeletal hyperostosis: differentiation from ankylosing spondylitis.

Radiology,

Radiographic and pathologic features of spinal involvement in diffuse idiopathic skeletal hyperostosis (DISH).

Curr Rheumatol Rep, 2021 Jan 26

Diffuse Idiopathic Skeletal Hyperostosis (DISH) and a Possible Inflammatory Component.

Arthritis Care Res (Hoboken), 2019 Jan

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

J Rheumatol, 2017 Dec 01

Short-term Repeat Magnetic Resonance Imaging Scans in Suspected Early Axial Spondyloarthritis Are Clinically Relevant Only in HLA-B27-positive Male Subjects.

Arthritis Rheumatol, 2019 Feb 06

Is it Useful to Repeat Magnetic Resonance Imaging of the Sacroiliac Joints After Three Months or One Year in the Diagnosis of Patients With Chronic Back Pain and Suspected Axial Spondyloarthritis?

Arthritis Rheum,

Ten years' experience with needle biopsy in the early diagnosis of sacroiliitis.

Arthritis Rheumatol, 2022 Feb 07

Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis.

Related Topics in Rheumatology